Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
28 September 2018Website:
http://gritstonebio.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 05 Jul 2024 23:09:46 GMTDividend
Analysts recommendations
Institutional Ownership
GRTS Latest News
LOS ANGELES, CA / ACCESSWIRE / July 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Gritstone bio, Inc. ("Gritstone" or "the Company") (NASDAQ:GRTS) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 9, 2023 and February 29, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before August 6, 2024.
NEW YORK, July 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Gritstone bio, Inc. (“Gritstone” or the “Company”) (NASDAQ: GRTS) and certain officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 24-cv-03640, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Gritstone securities between March 9, 2023 and February 29, 2024, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
NEW YORK, NY / ACCESSWIRE / July 7, 2024 / If you suffered a loss on your Gritstone bio, Inc. (NASDAQ:GRTS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gritstone-lawsuit-submission-form?prid=89479&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESSWIRE / July 7, 2024 / If you suffered a loss on your Gritstone bio, Inc. (NASDAQ:GRTS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gritstone-lawsuit-submission-form?prid=89477&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESSWIRE / July 7, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Gritstone bio, Inc. ("Gritstone" or "the Company") (NASDAQ:GRTS) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Gritstone securities between March 9, 2023, and February 29, 2024, inclusive (the "Class Period").
NEW YORK, NY / ACCESSWIRE / July 7, 2024 / If you suffered a loss on your Gritstone bio, Inc. (NASDAQ:GRTS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gritstone-lawsuit-submission-form?prid=89538&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESSWIRE / July 6, 2024 / If you suffered a loss on your Gritstone bio, Inc. (NASDAQ:GRTS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gritstone-lawsuit-submission-form?prid=89454&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESSWIRE / July 6, 2024 / If you suffered a loss on your Gritstone bio, Inc. (NASDAQ:GRTS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gritstone-lawsuit-submission-form?prid=89439&wire=1 or contact Joseph E. Levi, Esq.
LOS ANGELES, CA / ACCESSWIRE / July 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Gritstone bio, Inc. ("Gritstone" or "the Company") (NASDAQ:GRTS) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 9, 2023 and February 29, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before August 6, 2024.
NEW YORK, NY / ACCESSWIRE / July 5, 2024 / If you suffered a loss on your Gritstone bio, Inc. (NASDAQ:GRTS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gritstone-lawsuit-submission-form?prid=89262&wire=1 or contact Joseph E. Levi, Esq.
What type of business is Gritstone bio?
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate for the treatment of common solid tumors comprising metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and shared neoantigen-positive tumors. In addition, it develops CORAL, a SARS-CoV-2 vaccine platform designed to deliver spike and additional SARS-CoV-2 T cell epitopes for protection and broader immunity against SARS-CoV-2 variants; and a therapeutic vaccine candidate designed to treat and cure human immunodeficiency virus (HIV) infection. It has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
What sector is Gritstone bio in?
Gritstone bio is in the Healthcare sector
What industry is Gritstone bio in?
Gritstone bio is in the Biotechnology industry
What country is Gritstone bio from?
Gritstone bio is headquartered in United States
When did Gritstone bio go public?
Gritstone bio initial public offering (IPO) was on 28 September 2018
What is Gritstone bio website?
https://gritstonebio.com
Is Gritstone bio in the S&P 500?
No, Gritstone bio is not included in the S&P 500 index
Is Gritstone bio in the NASDAQ 100?
No, Gritstone bio is not included in the NASDAQ 100 index
Is Gritstone bio in the Dow Jones?
No, Gritstone bio is not included in the Dow Jones index
When does Gritstone bio report earnings?
The next expected earnings date for Gritstone bio is 09 August 2024